Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations?

Table 1 Studies that evaluated hepatocellular carcinoma risk in a cohort with cirrhosis or advanced fibrosis due to nonalcoholic steatohepatitis or cryptogenic cirrhosis (presumptively nonalcoholic steatohepatitis-related) and in a comparison cohort with hepatitis C virus-related cirrhosis or advanced fibrosis

Ref.	n	Age (yr)	Male gender (%)	HCC incidence	P value
Ratziu et al[22]	27 CC-O	62.1 ± 10.6	(M/F) 1.7	8/27 (29.6%)	NS
	85 HCV	62.1 ± 10.6	(M/F) 1.7	18/85 (21%)
Sanyal et al[23]	152 NASH	54.7 ± 11.6	39.7	10/149 (6.7%)	NS
	150 HCV	48.3 ± 11.3	64.8	25/147 (17%)
Kojima et al[24]	24 CC	58.2 ± 10.6	NA	9/24 (37.5%)	P < 0.01
	48 HCV	58.7 ± 8.1	NA	36/48 (75%)
Yatsuji et al[25]	68 NASH	62.7 ± 13.2	43	5-yr 11.3%	NS
	69 HCV	61.3 ± 5.8	43	5-yr 30.5%
Ascha et al[26]	195 NASH	56.6	44.1	Annual cumulative 2.6%	P = 0.09
	315 HCV	48.2	76.5	Annual cumulative 4.0%
Bhala et al[27]	247 NAFLD	54.7	39.5	6/247 (2.4%)	P = 0.03
	264 HCV	48.3	67.5	18/264 (6.8%)

NAFLD: Nonalcoholic fatty liver disease; HCC: Hepatocellular carcinoma; NASH: Nonalcoholic steatohepatitis; HCV: Hepatitis C virus; CC-O: Overweight patients with cryptogenic cirrhosis; (M/F): Male/female ratio; NS: Non-significant; CC: Cryptogenic cirrhosis.